A Double-blind, Placebo-controlled, Single Dose, Pharmacokinetic Study to Characterize the Central Brain Penetrance of JNJ-39393406 Using Cerebrospinal Fluid in Healthy Male and Female Subjects
Latest Information Update: 27 Jul 2013
At a glance
- Drugs JNJ 39393406 (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 19 Mar 2012 New trial record